The Sanger Institute, in collaboration with Open Targets, has launched the Open-IBD project ahead of World IBD Day. The initiative, funded with £11 million, aims to uncover new ways to predict, monitor, and treat Crohn's disease and ulcerative colitis. Open-IBD will involve genomics and immunology experts, gastroenterologists, and patients from across the UK. The project will study serial multi-omics and long-term outcomes from diagnosis in 1,000 people with inflammatory bowel disease (IBD).
On #WorldIBDDay, Open Targets project lead @anderson_carl introduces our most ambitious project yet: @OpenIBD! https://t.co/7cdoVpu2cn
Today is #WorldIBDDay 🌎 Check out our video with @anderson_carl to discover more about what IBD is and how @OpenIBD aims to find new ways to predict, monitor, and treat it.🔎 @OpenTargets @DrChrisLamb @UniofNewcastle @NewcastleHosps #IBDMythBusting https://t.co/TWqr00aM99 https://t.co/AO8VGThyLP
I’m supporting #WorldIBDDay to raise awareness of Crohn’s and Colitis and tackle #IBDMyths. Together, we can improve understanding of Inflammatory Bowel Disease and raise awareness of how it may affect people. Visit @CrohnsColitisUK to find out more: https://t.co/QiCtjtZ96H https://t.co/aa1Dof4qZS
Launching ahead of #WorldIBDDay, @OpenIBD is an ambitious project that aims to uncover new ways to predict, monitor, and treat #Crohnsdisease and #ulcerativecolitis 🔎 Read more about it here 👇 https://t.co/TWqr00aM99 https://t.co/EVZn1x2XOm
📣Introducing Open-IBD — our most ambitious project yet! @OpenIBD will bring together genomics and immunology experts, gastroenterologists, and patients from across the UK to identify new and personalised ways to predict, monitor, and treat inflammatory bowel disease https://t.co/bYHE7c0Tnd
📢 On World #IBD Day weekend @anderson_carl and I are delighted to introduce Open-IBD! £11M funding from @OpenTargets and @sangerinstitute @OpenIBD will study serial multi-omics and longterm outcomes from diagnosis in 1,000 people with IBD More👇 https://t.co/lArpRIHdGj https://t.co/NyscSQDECA